We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dyax and ICOS Enter Into License Agreement for Discovery of Therapeutic Antibodies
News

Dyax and ICOS Enter Into License Agreement for Discovery of Therapeutic Antibodies

Dyax and ICOS Enter Into License Agreement for Discovery of Therapeutic Antibodies
News

Dyax and ICOS Enter Into License Agreement for Discovery of Therapeutic Antibodies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dyax and ICOS Enter Into License Agreement for Discovery of Therapeutic Antibodies "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dyax Corp. has announced that it has granted a non-exclusive license to its proprietary phage display libraries to ICOS Corporation for the discovery and development of therapeutic antibodies.

Under the terms of the agreement, Dyax receives technology license fees from ICOS, as well as clinical milestone payments and royalties on net sales of any products that may result from ICOS's use of the Dyax libraries.

The agreement provides ICOS with a license to Dyax's antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology.

Henry E. Blair, Chairman and Chief Executive Officer of Dyax commented, "I'm pleased with the industry recognition of the value of our antibody technology and the sustained growth in Dyax's revenue-generating collaborations, as evidenced by this addition of ICOS to our long list of licensees."

"This arrangement will allow ICOS to utilize Dyax's state-of-the-art libraries of fully human monoclonal antibodies. We look forward to working with the talented team at ICOS, and to potential products moving forward under this license."

Advertisement